News
A University of Dundee spinout has announced a multi-million pound deal to develop first-in-class therapeutics that restore the body's natural disease suppression processes.
News
A University of Dundee spinout has announced a multi-million pound deal to develop first-in-class therapeutics that restore the body's natural disease suppression processes.
Press release
Some of Scotland’s brightest business prospects are preparing for an exciting future after being crowned winners of a major Scottish competition.
News
Parliamentarians from across the political spectrum today heard how University of Dundee research could help save millions of lives in low- and middle-income countries (LMICs)
News
A prestigious audience of policy makers, entrepreneurs and scientists from across the UK will hear about Dundee’s world-leading expertise in drug discovery at next month’s Braemar Summit.
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.
Press release
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
Press release
A near-£1 million investment will help University of Dundee spinout company Ten Bio Ltd to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals.
Press release
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases.
Press release
Work to build on Dundee’s world-class expertise in biomedical sciences is set to begin in earnest after the ‘Growing the Tay Cities Biomedical Cluster’ project was officially signed off by the Tay Cities Region Joint Committee today (February 19).
Press release
A University of Dundee spinout company developing treatments for eczema, rheumatoid arthritis and other inflammatory conditions has completed its first round of private investment.
News
The o2h human health EIS Fund has announced its intention to lead an investment into In4Derm.
Press release
Three spinout projects from the University of Dundee with the potential to deliver significant healthcare benefits have received more than £250,000 from Scottish Enterprise to support their development.
Press release
The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need.
Press release
Researchers at the University of Dundee are looking to transform pharmaceutical and cosmetics testing with their spinout venture that offers an alternative for many experiments currently only performed in animals.
News
The finalists for Converge 2020, Scotland’s leading academic company creation programme, have been announced with representation from the School included on the list with Dr Robyn Hickerson, Co-founder and Chief Scientific Officer of Ten Bio.
Press release
University of Dundee researchers hope to turn their spinout venture into a biotech company worth hundreds of millions of pounds by helping to treat people with eczema, rheumatoid arthritis and other inflammatory conditions.
Press release
The Universities of Dundee and Edinburgh are playing key roles in a €77.7 million pan-European consortium seeking to accelerate the development of therapies for Covid-19 and future coronaviruses.
Press release
The University of Dundee is working with partners around the world to rapidly repurpose existing drugs against Covid-19.
Press release
The University of Dundee Drug Discovery Unit is delighted to announce it has licensed assets to Corbin Therapeutics to develop possible new treatments for neuroinflammation-based disorders, including multiple sclerosis (MS).
News
Evotec invests in Exscientia to advance AI-driven drug discovery